Literature DB >> 3040238

Formation of blocking lesions at identical DNA sequences by the nitrosourea and platinum classes of anticancer drugs.

J D Gralla, S Sasse-Dwight, L G Poljak.   

Abstract

cis-Diamminedichloroplatinum (II) (cisplatin) compounds and the chloroethylnitrosoureas are two different classes of anticancer drugs that work by modifying DNA covalently. We have compared the platinating drug cisplatin with the alkylating drug bischloroethylnitrosourea and other chloroethylnitrosoureas by modifying double stranded DNA in vitro and identifying blocking lesions that impede the progress of Escherichia coli DNA polymerase. Despite their very different structures and reactivities, cisplatin and the chloroethylnitrosoureas from primary blocking lesions at identical sequences, those containing adjacent guanosines on the same DNA strand. In tumor virus SV 40 DNA, a very strong target for both types of drugs is the regulatory sequence GGGCGG, which is repeated six times and is an important sequence for viral replication and an essential sequence for expression of the viral transforming gene. Sequences related to these GC box elements are known to be present in the flanking regions of many retroviruses and oncogenes, thus raising the possibility that the targeting of these sequences in tumor cells contributes to drug activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040238

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase.

Authors:  M Ponti; S M Forrow; R L Souhami; M D'Incalci; J A Hartley
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

2.  Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent.

Authors:  J N Burstyn; W J Heiger-Bernays; S M Cohen; S J Lippard
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

3.  Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA.

Authors:  M A Lemaire; A Schwartz; A R Rahmouni; M Leng
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

4.  The interaction of DNA-targeted platinum phenanthridinium complexes with DNA.

Authors:  J Whittaker; W D McFadyen; G Wickham; L P Wakelin; V Murray
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

5.  Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo.

Authors:  J S Mymryk; E Zaniewski; T K Archer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

6.  Lack of evidence for a high-affinity sarcosinamide carrier or a catecholamine carrier in Calu-1 lung-cancer cells, HT-29 colon-cancer cells, and DHF fibroblasts.

Authors:  A Malapetsa; J L Bramson; A J Noë; L C Panasci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Sites of termination of in vitro DNA synthesis on cis-diamminedichloroplatinum(II) treated single-stranded DNA: a comparison between E. coli DNA polymerase I and eucaryotic DNA polymerases alpha.

Authors:  G Villani; U Hübscher; J L Butour
Journal:  Nucleic Acids Res       Date:  1988-05-25       Impact factor: 16.971

8.  Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.

Authors:  M A Alaoui-Jamali; L Panasci; G M Centurioni; R Schecter; S Lehnert; G Batist
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.